# Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

> **NCT03045887** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 38 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK2292767 50 μg
- **DRUG:** GSK2292767 500 μg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03045887
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-06
- **Primary completion:** 2017-08-11
- **Final completion:** 2017-08-16
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045887, "Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03045887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*